poster

Relapse in Adequately Versus Not Adequately Treated Black or African American Patients With Schizophrenia Transitioned to Paliperidone Palmitate Once-Every-3-Months Injection: A Retrospective Analysis

Abstract: Purpose: Paliperidone palmitate once-every-3-months (PP3M), a long-acting injectable antipsychotic, is indicated for adults with schizophrenia adequately treated (AT) with palip...

01/19/2023

Long-Term Safety and Efficacy of Esketamine Nasal Spray in Black and/or African American Adults With Treatment-Resistant Depression: A Subgroup Analysis of the SUSTAIN-3 Study

Abstract: Purpose: This subgroup analysis of SUSTAIN-3 (NCT02782104), an ongoing open-label extension study of esketamine nasal spray (ESK), assessed long-term safety and efficacy of flex...

01/19/2023

State- and County-Level Antipsychotic Utilization, Healthcare Resource Use and Costs, and Quality of Care among Medicare Beneficiaries with Schizophrenia in the United States

Abstract: Objective: To examine the regional variation in schizophrenia care, as measured by antipsychotic (AP) utilization, healthcare resource utilization (HRU) and associated costs, an...

01/19/2023

Efficacy and Acceptability of Vitamin D Supplements for Depressed Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Abstract: Objective: This systematic review and meta-analysis synthesized the evidence from randomized controlled trials (RCTs) to compare depressive symptom reduction and all-cause dropo...

01/19/2023

Real-World Characteristics of U.S. Patients Living with Schizophrenia or Schizoaffective Disorder Who Experience Relapse

Abstract: Relapse (i.e., acute exacerbations of symptoms) is common among patients living with schizophrenia leading to employment, economic, and social instability. The objective of this...

01/19/2023

Real-world Persistency Outcomes associated with Pimavanserin vs other-AAPs for Parkinson’s Disease Psychosis: Analysis of Medicare Beneficiaries from 100% Sample

Abstract: OBJECTIVES: Treatment persistence (i.e., measure of real-world treatment utilization relative to patient preference) with pimavanserin (PIM), the only FDA approved atypical anti...

01/19/2023

Systematic Literature Review of Studies Reporting Quality of Life or Functional Outcome Measures in People with Negative Symptoms of Schizophrenia

Abstract: Aim Negative symptoms of schizophrenia (NSS) have been linked to poor quality of life (QoL) and impaired functional outcomes. A systematic literature review was performed to ide...

01/19/2023

Subjective Ratings of Medication Strength of Lemborexant Over 6 Months in Subjects With Moderate or Severe Insomnia

Abstract: Introduction: A concern with sedative-hypnotic medication for the treatment of insomnia is the development of tolerance. The Patient Global Impression–Insomnia (PGI-I) and Insom...

01/19/2023

The Incidence of Abnormal Dreams and Nightmares in Adults With Insomnia Treated With Lemborexant: Results From Two Phase 3 Studies

Abstract: Introduction: Abnormal dreams and nightmares are reported by patients with insomnia both before and after treatment with hypnotics. Dual orexin receptor antagonists such as lemb...

01/19/2023

Efficacy and Safety of Early Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: A Duration of Illness Meta-Analysis

Abstract: Background: Although long-acting injectable antipsychotics (LAIs) are often reserved for patients with chronic schizophrenia, emerging evidence suggests that LAIs may reduce the...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products